“GLP-1s cause eating disorders.”
What the evidence shows
There is no good evidence that GLP-1 drugs cause eating disorders in people who don't have them. If anything, early research points the other way: small studies and case series suggest semaglutide and similar drugs can reduce binge-eating episodes and loss-of-control eating, and GLP-1s are being actively studied as a possible treatment for binge eating disorder. At the same time, clinicians and eating-disorder organizations flag a genuine, specific concern: for someone with a current or past eating disorder, powerful appetite suppression and rapid weight loss can reinforce restriction, mask warning signs, or complicate recovery.
What we still don’t know
None of this is settled. The binge-eating data are early, small, and short, with no GLP-1 approved for any eating-disorder indication. We don't know how often, or in whom, these drugs might tip vulnerable people toward restrictive patterns, because that hasn't been rigorously studied — the risk is a well-reasoned caution, not a measured rate. People in larger bodies with atypical anorexia or non-purging bulimia can also be misread as candidates for weight-loss medication, which muddies the picture further.
Why the claim misleads
"Cause eating disorders" states as a general fact something the evidence doesn't support for the population at large, while erasing the part that's actually important: the risk is concentrated in people with a disordered-eating history, for whom effortless appetite suppression is a hazard rather than a benefit. That's a reason for careful screening and clinician involvement (see the eating-disorder discussion), not a blanket claim that the drugs manufacture eating disorders.
Graded by The Peptide Era · evidence, not hype